Bayer’s Adaptive Pathways Experience: 'Disappointing', But Valuable Lessons Learned
Executive Summary
Bayer outlined its initial experience with the European Medicines Agency’s adaptive pathways pilot at the recent DIA EuroMeeting in Glasgow, saying that the process had been “disappointing” but that it had learned some valuable lessons.
You may also be interested in...
EMA Defends Adaptive Pathways Against Fresh Attack Following Pilot Report
The European Medicines Agency has dismissed a call to stop accepting applications for its adaptive pathways program until it has better evidence on how to use real-world data.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.